Flagship dialysis care, Fresenius 5008S CorDiax stays central in clinics
15.06.2026 - 18:01:00 | ad-hoc-news.de
Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 3:59 PM ET. Details in the imprint.
The 5008S CorDiax hemodialysis system from Fresenius Medical Care remains one of the company’s flagship machines in dialysis clinics, combining high-volume treatment capacity with advanced monitoring and safety features for chronic kidney disease patients.
Flagship system for high-efficiency dialysis therapy
Fresenius Medical Care describes the 5008S CorDiax as a hemodialysis platform that supports both standard high-flux dialysis and the firm’s proprietary high-volume hemodiafiltration therapy, designed to increase convective clearance of middle molecules during treatment.
The system is built for use in busy dialysis centers, offering automated workflows, integrated treatment data capture and compatibility with the company’s HD and HDF disposables, which helps clinics standardize their setups and streamline training across treatment stations.
Fresenius positions high-volume hemodiafiltration on the 5008S CorDiax as a way to enable higher substitution volumes while maintaining stable treatment conditions, aiming to improve removal of larger uremic toxins compared with conventional high-flux hemodialysis.
The device integrates automatic blood volume monitoring and online clearance measurement features, giving clinicians real-time insight into treatment adequacy and intradialytic fluid status to support individualized dialysis prescriptions.
According to company materials, the 5008S CorDiax is part of Fresenius Medical Care’s broader portfolio of chronic dialysis products, which includes machines, dialyzers, concentrates and digital tools used across its own clinics and external customers.
Fresenius SE & Co. KGaA, the parent group of Fresenius Medical Care, continues to derive a significant share of its revenue from dialysis-related products and services worldwide, making systems such as the 5008S CorDiax strategically important within its healthcare portfolio.
Shares of Fresenius SE & Co. KGaA (DE0005785604) traded on Xetra at EUR 27.76 on 06/14/2026.
Fresenius 5008S CorDiax in brief: the hard facts
- Product: 5008S CorDiax hemodialysis system
- Manufacturer: Fresenius SE & Co. KGaA
- Category: Flagship/Bestseller hemodialysis machine
- Launch date: Not specified publicly; part of the 5008 platform, commercially established
- MSRP / Price: Not publicly disclosed; sold via tenders and institutional purchasing
- Availability: Marketed to dialysis centers in Europe and other global regions through Fresenius Medical Care
- Target audience: Professional dialysis providers and hospital-based renal units treating chronic kidney disease
- Key differentiator / USP: Support for high-volume hemodiafiltration with integrated monitoring for treatment adequacy and blood volume
More on Fresenius and its dialysis focus
Additional coverage on Fresenius and its dialysis portfolio, including the 5008S CorDiax system and related renal care products, can be found in the ad hoc news topic overview and in the company’s investor materials.
More Fresenius coverage Investor RelationsThis article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.
